Please login to the form below
FibroGen
This page shows the latest FibroGen news and features for those working in and with pharma, biotech and healthcare.
FDA requests further safety trials for AZ, FibroGen’s roxadustat
The FDA advisory committee then voted against approval of roxadustat. AstraZeneca and FibroGen have said that they are working together to “evaluate next steps”.
Latest news
-
FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
The committee members concluded that AZ and FibroGen should produce additional safety data for roxadustat in this indication prior to marketing of the drug. ... Although we are disappointed by today’s outcome, we will continue to work closely with our
-
FDA questions safety profile of AZ, FibroGen’s anaemia drug roxadustat
AZ and FibroGen are aiming for approval of roxadustat in anaemia caused by chronic kidney disease. ... AZ and FibroGen are aiming for approval of roxadustat for the treatment of anaemia caused by chronic kidney disease (CKD).
-
CHMP recommends eight new medicines for EU approval
Finally, the CHMP has adopted positive opinions for Astellas and FibroGen’s Evrenzo (Roxadustat) for the treatment of anaemia symptoms in chronic kidney disease patients.
-
Astellas files new application for expanded use of roxadustat in Japan
Together with partner FibroGen, Astellas has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare to gain marketing approval for roxadustat. ... AstraZeneca hold the development and commercialisation
-
EU, US biotechs merge to create fibrosis, cancer player
Esbriet has since been joined on the market by Boehringer Ingelheim's Ofev (nintedanib), approved in 2014, with other new agents in trials including AstraZeneca’s saracatinib, Galapagos’ GLPG1690 and
More from news
Approximately 4 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
-
China: AstraZeneca’s new engine for growth and innovation
FibroGen in China for patients with anaemia in chronic kidney disease.
-
Pharma deals during July 2013
AstraZeneca's (AZ) $815m development and commercialisation collaboration with FibroGen for FG-4592 scooped up the territories that had not already been taken by Astellas, in the agreement the Japanese pharma ... While AZ will be responsible for
-
Deal Watch table for July 2013
818. FibroGen / AstraZeneca. Strategic collaboration. FG-4592, oral treatment for anaemia in renal disease (p2/3).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
The latest movers in pharma. FibroGen . FibroGen has appointed Enrique Conterno (pictured below, left) as its chief executive officer, after he recently retired from his role as senior vice president for ... This is a tremendously exciting time for
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
